Switzerland · Biotechnology startup
Switzerland · ESBATech
ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework.
Funding reportedLast round: Series B
What company datasets say ESBATech raised
Funding, as reported
Reported in all72Min the source's currency
Rounds3
Last roundSeries B
Last round dateAug 2008
Investors listed8
Biotechnology in Switzerland
Startups like it
Is this your company?
Add your raise, your deck and your story, and put ESBATech in front of investors. Or tell us what we have wrong.